Tempus AI (NASDAQ:TEM) CEO Eric Lefkofsky Sells 166,250 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 166,250 shares of Tempus AI stock in a transaction that occurred on Wednesday, January 28th. The stock was sold at an average price of $65.56, for a total value of $10,899,350.00. Following the completion of the sale, the chief executive officer directly owned 8,941,533 shares in the company, valued at $586,206,903.48. This represents a 1.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Tempus AI Trading Down 5.8%

Shares of TEM stock opened at $59.82 on Friday. Tempus AI, Inc. has a fifty-two week low of $36.22 and a fifty-two week high of $104.32. The firm has a market capitalization of $10.64 billion, a P/E ratio of -50.27 and a beta of 5.22. The stock’s fifty day moving average is $68.56 and its two-hundred day moving average is $73.89. The company has a debt-to-equity ratio of 2.45, a quick ratio of 3.12 and a current ratio of 3.28.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Tuesday, November 4th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. Tempus AI had a negative net margin of 18.45% and a negative return on equity of 73.21%. The business had revenue of $334.21 million during the quarter, compared to analysts’ expectations of $328.89 million. During the same period in the prior year, the business earned ($0.46) earnings per share. The company’s quarterly revenue was up 84.7% compared to the same quarter last year. Research analysts expect that Tempus AI, Inc. will post -6.15 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TEM has been the subject of several analyst reports. BTIG Research upped their target price on Tempus AI from $96.00 to $105.00 and gave the company a “buy” rating in a report on Tuesday, November 25th. HC Wainwright cut their price objective on shares of Tempus AI from $98.00 to $89.00 and set a “buy” rating for the company in a research report on Friday, November 7th. TD Cowen lowered shares of Tempus AI from a “buy” rating to a “hold” rating in a report on Tuesday, October 21st. Canaccord Genuity Group reduced their price target on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, December 22nd. Finally, Piper Sandler reduced their target price on Tempus AI from $105.00 to $80.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 11th. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Tempus AI presently has an average rating of “Hold” and an average target price of $87.20.

Institutional Trading of Tempus AI

Several hedge funds have recently made changes to their positions in TEM. GC Wealth Management RIA LLC purchased a new position in Tempus AI in the 4th quarter valued at approximately $399,267,000. Vanguard Group Inc. raised its stake in shares of Tempus AI by 22.1% in the third quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock valued at $762,032,000 after acquiring an additional 1,706,837 shares in the last quarter. Voloridge Investment Management LLC raised its stake in shares of Tempus AI by 183.0% in the third quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock valued at $129,708,000 after acquiring an additional 1,039,176 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in Tempus AI by 312.7% in the third quarter. BNP Paribas Financial Markets now owns 1,274,549 shares of the company’s stock valued at $102,869,000 after purchasing an additional 965,730 shares during the period. Finally, AQR Capital Management LLC acquired a new position in Tempus AI during the 2nd quarter worth $54,020,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.